Repatha Performance Contracting: Sweetening The Pot For Payers
Executive Summary
Amgen suggests it would respond to payer price concerns by pursuing contracts that tie the drug’s net cost (after rebates) to its value in the relatively narrow population it is indicated for. Some payers eye choosing either Repatha or rival Praluent based on price.